These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31611591)

  • 1. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy.
    Lin CC; Hsu CW; Chen YC; Chang ML; Liang KH; Lai MW; Lin CL; Chien RN; Lin KH; Yeh CT
    Pharmacogenomics J; 2020 Feb; 20(1):57-68. PubMed ID: 31611591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.
    Lin WR; Hsu CW; Yeh CS; Chen YC; Chang ML; Liang KH; Lin CC; Chu YD; Yeh CT
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e54-e63. PubMed ID: 28695683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
    Yeh CT; Liang KH; Lin CC; Chang ML; Hsu CL; Hung CF
    Int J Cancer; 2014 Mar; 134(5):1214-24. PubMed ID: 23959947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.
    Lin CL; Chien RN; Chen LW; Chu YD; Yeh CT
    Cancer Biomark; 2023; 36(3):251-266. PubMed ID: 36938726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
    Nagai H; Mukozu T; Ogino YU; Matsui D; Matsui T; Wakui N; Momiyama K; Igarashi Y; Sumino Y; Higai K
    Anticancer Res; 2015 Apr; 35(4):2269-77. PubMed ID: 25862889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
    Liang KH; Lin CC; Yeh CT
    Pharmacogenomics; 2011 Jul; 12(7):1061-73. PubMed ID: 21635146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
    Terashima T; Honda M; Toyama T; Shimakami T; Shimizu R; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1813-1820. PubMed ID: 32180251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
    Fukubayashi K; Tanaka M; Izumi K; Watanabe T; Fujie S; Kawasaki T; Yoshimaru Y; Tateyama M; Setoyama H; Naoe H; Kikuchi K; Sasaki Y
    Cancer Med; 2015 Aug; 4(8):1214-23. PubMed ID: 26044168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
    Kang MK; Park JG; Lee HJ
    Medicine (Baltimore); 2018 Apr; 97(17):e0611. PubMed ID: 29703062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Lyu N; Wang X; Li JB; Lai JF; Chen QF; Li SL; Deng HJ; He M; Mu LW; Zhao M
    J Clin Oncol; 2022 Feb; 40(5):468-480. PubMed ID: 34905388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
    Hatooka M; Kawaoka T; Aikata H; Inagaki Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Masaki K; Waki K; Kohno H; Kohno H; Moriya T; Nagaoki Y; Tamura T; Amano H; Katamura Y; Chayama K
    BMC Cancer; 2018 Jun; 18(1):633. PubMed ID: 29866075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.
    Saeki I; Yamasaki T; Maeda M; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
    PLoS One; 2019; 14(6):e0218136. PubMed ID: 31194789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Zhuang BW; Li W; Xie XH; Hu HT; Lu MD; Xie XY
    Jpn J Clin Oncol; 2019 Sep; 49(9):845-855. PubMed ID: 31063184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
    Kanekawa T; Nagai H; Kanayama M; Sumino Y
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):899-909. PubMed ID: 25138286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients.
    Moriya K; Namisaki T; Sato S; Furukawa M; Douhara A; Kawaratani H; Kaji K; Shimozato N; Sawada Y; Saikawa S; Takaya H; Kitagawa K; Akahane T; Mitoro A; Yamao J; Yoshiji H
    Clin Mol Hepatol; 2019 Dec; 25(4):381-389. PubMed ID: 31405269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
    Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.